BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,585,520 | -16.8% | 52,674 | -0.2% | 0.00% | 0.0% |
| Q2 2023 | $4,310,554 | -85.4% | 52,806 | -86.7% | 0.00% | -90.0% |
| Q1 2023 | $29,523,169 | -68.9% | 397,940 | -65.2% | 0.01% | -69.7% |
| Q4 2022 | $94,817,289 | +11.8% | 1,144,031 | +283.0% | 0.03% | +3.1% |
| Q3 2022 | $84,838,000 | -48.5% | 298,721 | -37.1% | 0.03% | -43.9% |
| Q2 2022 | $164,603,000 | -30.4% | 474,852 | -13.1% | 0.06% | -18.6% |
| Q1 2022 | $236,515,000 | -37.2% | 546,175 | -25.0% | 0.07% | -32.0% |
| Q4 2021 | $376,642,000 | -2.9% | 728,035 | -9.0% | 0.10% | -8.8% |
| Q3 2021 | $387,863,000 | +6.7% | 800,429 | -0.9% | 0.11% | +6.6% |
| Q2 2021 | $363,627,000 | +5.2% | 807,594 | -10.7% | 0.11% | 0.0% |
| Q1 2021 | $345,574,000 | +18.2% | 904,808 | -1.7% | 0.11% | +12.8% |
| Q4 2020 | $292,352,000 | +33.6% | 920,647 | +4.2% | 0.09% | +19.0% |
| Q3 2020 | $218,821,000 | -3.1% | 883,306 | +3.3% | 0.08% | -11.2% |
| Q2 2020 | $225,714,000 | +33.7% | 854,752 | -4.0% | 0.09% | +11.2% |
| Q1 2020 | $168,786,000 | -4.5% | 890,124 | +10.6% | 0.08% | +21.2% |
| Q4 2019 | $176,684,000 | -5.1% | 804,902 | -15.4% | 0.07% | -12.0% |
| Q3 2019 | $186,141,000 | -2.9% | 951,301 | +3.4% | 0.08% | -3.8% |
| Q2 2019 | $191,728,000 | +12.9% | 919,601 | +7.5% | 0.08% | +8.3% |
| Q1 2019 | $169,885,000 | +46.1% | 855,625 | +6.5% | 0.07% | +28.6% |
| Q4 2018 | $116,303,000 | -16.0% | 803,633 | +18.5% | 0.06% | -1.8% |
| Q3 2018 | $138,381,000 | +56.4% | 677,968 | +13.4% | 0.06% | +50.0% |
| Q2 2018 | $88,475,000 | +26.5% | 598,005 | +29.1% | 0.04% | +26.7% |
| Q1 2018 | $69,966,000 | +516.5% | 463,234 | +428.8% | 0.03% | +500.0% |
| Q4 2017 | $11,349,000 | +8.6% | 87,605 | +1.3% | 0.01% | 0.0% |
| Q3 2017 | $10,451,000 | -10.4% | 86,451 | -12.9% | 0.01% | 0.0% |
| Q2 2017 | $11,664,000 | +5.1% | 99,267 | -9.0% | 0.01% | 0.0% |
| Q1 2017 | $11,094,000 | +29.0% | 109,137 | +30.5% | 0.01% | +25.0% |
| Q4 2016 | $8,599,000 | – | 83,622 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |